Patent Battle Erupts in Europe: ToolGen Sues Lonza Over CRISPR Technology Infringement Amidst Gene Therapy Breakthroughs
SEOUL, South Korea — ToolGen, a prominent player in genome editing, has initiated legal proceedings against Dutch manufacturer Lonza Netherlands B.V. The lawsuit, filed in The Hague, alleges that Lonza infringes on ToolGen’s patent rights while producing CASGEVY, the first authorized CRISPR-based gene therapy for treating sickle cell disease and beta-thalassemia. According to the claims, Lonza’s production processes at its Dutch facility violate ToolGen’s European patent (EP 4 357 457), which is centered on the CRISPR-Cas9 RNP technology. CASGEVY, developed collaboratively by Vertex Pharmaceuticals and CRISPR Therapeutics, has gained regulatory approval in multiple regions, including … Read more